Earnings ·
BrainStorm Cell Therapeutics Inc. reported second quarter 2026 financial results and provided a corporate update on…
BCLIBrainstorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. reported second quarter 2026 financial results and provided a corporate update on August 14, 2026. The company announced the appointment of Peter J. Pitts as Executive Chairman to lead regulatory and operational initiatives for its NurOwn program in ALS. Financially, the firm reported a net loss of approximately $3.9 million, or $(0.35) per share, compared to a $2.9 million loss in the prior year period. General and administrative expenses rose to $2.7 million from $1.5 million, while R&D expenditures decreased slightly to $1 million. Cash reserves declined to approximately $0.2 million as of June 30, 2026. The company is preparing to initiate the Phase 3b ENDURANCE trial for NurOwn under a Special Protocol Assessment with the FDA. BrainStorm Cell Therapeutics Inc. operates in the biotechnology industry, developing adult stem cell therapeutics for neurodegenerative diseases.